Business
Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has achieved an impressive Net Promoter Score (NPS) of 55 for the time period representing FY2025 (April 2024 – March 2025). This serves as a testament to the Company's ongoing dedication to excellence and collaboration.
About this update from Piramal Pharma Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"Piramal Pharma Solutions recently achieved a net promoter score (NPS) of 55, far surpassing industry averages. ","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"A third-party provider, DNV, validated the NPS survey and score. ","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"This accomplishment reflects the Organization's dedication to stakeholder centricity and operational excellence. ","length":116,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":290,"olType":false},{"type":"text","content":"MUMBAI, India, Dec. 15, 2025 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has achieved an impressive Net Promoter Score (NPS) of 55 for the time period representing FY2025 (April 2024 – March 2025). This serves as a testament to the Company's ongoing dedication to excellence and collaboration.","length":440,"tagName":"p"},{"type":"image","alt":"Peter DeYoung, CEO, Piramal Global Pharma","displaySize":"","headline":null,"caption":"Peter DeYoung, CEO, Piramal Global Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":320,"height":400,"url":"https://media.zenfs.com/en/cnwgroup.com/2f671b3a62baa3132a8ec2edad2facb7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1dzjI6fxdhtLEDiJ3ckB6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTgwMDtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/2f671b3a62baa3132a8ec2edad2facb7","width":320,"height":400}},"href":"https://mma.prnewswire.com/media/2845173/Peter_DeYoung_CEO_Piramal_Global_Pharma.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"NPS is a widely recognized metric for gauging customer loyalty, measuring how likely customers are to recommend a given product or service to their peers. Piramal Pharma Solutions conducts annual customer and promoter surveys to assess its performance and ensure responsiveness to clients' evolving needs. These surveys are coordinated by the Company's Customer Centricity team and validated by DNV, a third-party expert in assurance and risk management, ensuring accuracy and accountability.","length":500,"tagName":"p"},{"type":"text","content":"The insights gained from these surveys are thoroughly an...